FDA Class I Recall: Abbott FreeStyle Libre 3 Continuous Glucose Monitoring System
Friday, 6 September 2024, 10:05
Overview of FDA's Class I Recall
The FDA has announced a Class I recall affecting the Abbott FreeStyle Libre 3 continuous glucose monitoring (CGM) system. This decision comes after concerns regarding the functionality of the FreeStyle Libre 3 sensor, pivotal for many individuals managing diabetes.
Details on the FreeStyle Libre 3 System
- The FreeStyle Libre 3 is a continuous glucose monitor designed to give real-time glucose readings.
- Abbott’s FreeStyle Libre series generated impressive revenue, approximately $1.4 billion last year.
- Patients depend on the reliability of these systems for effective diabetes management.
What Patients Should Do
- Consult healthcare providers regarding this recall and its impact on glucose monitoring.
- Consider alternative glucose monitoring options if recommended.
- Stay informed about updates from Abbott and the FDA.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.